Corporate finance dominated health and biotech news, with a clinical-stage CNS specialist tapping fresh institutional capital, a pharma major refinancing in the bond markets, a boardroom transition at a fibrosis-focused drug repurposer, and a small debt conversion at a tissue-engineering group. The moves ranged widely in scale but shared a common thread: companies shoring up balance sheets and governance to support pipeline progress.
Solvonis raises £1.3m for CNS pipeline
Solvonis Therapeutics (LSE:SVNS) has conditionally raised gross proceeds of £1.3m through a placing of 1.08bn new shares at £0.0012 each, a discount of roughly 14% to the prior closing price. The news coincided with a sharp move in the stock, which fell 10.7% to 0.125p, reflecting the dilutive effect of the placing on existing holders even as it secures near-term funding for the company's central nervous system drug programmes.
The raise draws in new institutional investors alongside existing backers and installs Turner Pope as the company's new corporate broker. Net proceeds will fund three priority programmes: assessing the addition of European Union sites to the ongoing SVN-001 Phase 3 study in severe alcohol use disorder, advancing SVN-002 toward a US Investigational New Drug submission and Phase 2b readiness following positive pharmacokinetic bridging data reported in June, and supporting programme-management work on SVN-015 as it progresses through the US National Institute on Drug Abuse's Addiction Treatment Discovery Program.
"This fundraising supports clear next steps across our three priority programmes," said Anthony Tennyson, Chief Executive of Solvonis Therapeutics.
The financing buys Solvonis time against three concrete clinical catalysts rather than a single binary event, spreading risk across CNS and addiction-treatment indications with separate regulatory pathways. But the 14% discount and scale of the share issuance underline the persistent capital intensity of clinical-stage biotech: as a pre-revenue company, Solvonis remains wholly reliant on external financing to reach its next value-inflection points, and further dilution is likely if the EU trial expansion or the SVN-002 IND filing require additional funding before data reads out.
AstraZeneca prices €2.55bn four-tranche bond offering
AstraZeneca (LSE:AZN) said its wholly owned subsidiary, AstraZeneca Finance, priced four tranches of Eurobonds totalling €2.55bn on 24 August, a refinancing move that landed alongside a 2.8% rise in the shares to 12,450p. The pharmaceutical group, which develops and sells prescription medicines in oncology, rare disease and biopharmaceuticals across more than 125 countries, said the offering aligns with its long-term funding strategy.
The notes span maturities from 2030 to 2038 across four separate tranches. A €700m tranche carries a 3.402% coupon maturing 1 March 2030, a €600m tranche carries a 3.652% coupon maturing 1 September 2032, and a €500m tranche carries a 3.923% coupon maturing 1 September 2035. The largest slice, at €750m, carries a 4.169% coupon and matures 1 September 2038.
Laddering maturities across nearly a decade gives AstraZeneca flexibility to manage refinancing risk without concentrating repayment obligations in any single year, a standard treasury tactic for a company of its scale. The pricing terms, with coupons rising from 3.4% to 4.2% as tenor lengthens, reflect current market conditions for high-grade pharmaceutical credit rather than any company-specific concern, and the proceeds support general corporate purposes as the group continues to fund its extensive oncology and rare disease pipeline.
Nuformix names Tim Metcalfe as new Chairman
Nuformix (LSE:NFX), a drug repurposing company targeting fibrosis and oncology, has appointed Tim Metcalfe as Non-Executive Chairman and Director with effect from 1 September, as the shares eased 3% to 0.16p. He succeeds Dr Julian Gilbert, who steps down from the board on 31 August for personal reasons but will continue supporting the company in a consultancy capacity.
Metcalfe brings more than 30 years of City experience, having held senior roles at Robert Fleming, Rothschild, Westhouse Securities and Northland Capital Partners, served as Joint CEO of Zeus Capital, and co-founded investor relations adviser IFC Advisory in 2015. "I am delighted to be joining Nuformix as its new Chairman," Metcalfe said, while Gilbert added he would continue to support the company in a consultancy capacity as it seeks to maximise the value of its NXP002 programme.
The handover brings a heavyweight City network and decades of capital-markets experience to a company whose near-term prospects hinge on advancing the NXP002 programme and ongoing partnering discussions. For a small-cap repurposing specialist, a chairman with deep broking and investor-relations pedigree could prove valuable in securing partnership terms or future financing on better footing than the company might otherwise command.
BSF Enterprise converts loan notes to equity
BSF Enterprise (LSE:BSFA), the biotechnology company focused on tissue engineering, lab-grown materials and bioactive solutions, said Indigo Capital Investments has exercised a notice to convert £100,283 of the £1m outstanding under the company's convertible loan note instrument. The shares fell 8% to 1.15p as the conversion diluted the register, with BSF issuing 10m new shares of 1 penny each to Indigo, ranking equally with existing shares.
Following the issue, BSF's total issued share capital and voting rights will stand at 203.75m shares. The conversion trims roughly 10% of the debt owed under the loan note facility, leaving £900,717 still outstanding.
The move is modest in scale relative to the full loan facility but signals Indigo's willingness to take equity rather than cash repayment, easing near-term pressure on BSF's balance sheet at the cost of further dilution. With the bulk of the instrument still outstanding, further conversions-and further dilution-remain a live possibility for shareholders.
